

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description These results were generated using Mini-Sentinel Modular Program #3 (MP#3) Version 1.1. Each of the 16 Data Partners who responded to the request ran the program a total of 4 times (2 different care setting groups for the outcomes of interest times 2 different pre-existing condition characteristics). The query was run against the Mini-Sentinel Distributed Database and was distributed on October 5, 2011.

Results provide counts of incident users, dispensings, and total days supplied of aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone with a washout periods of 183 days. Results also provide counts of either of two adverse events among users: (1) anaphylactic shock and reaction (ICD-9-CM code 995.0), or (2) angioedema (ICD-9-CM code 995.1). For all runs, the event washout period was set to 183 days. The maximum allowable treatment gap was set to 30 days, the minimum episode duration was set to 0 days, and the minimum episode days supplied was set to one day. The program was run from August 1, 2009 to September 30, 2011. The two different care setting groups were: (1) IP and ED only (labeled "No Outpatient Visits" in Tables of Results), and (2) IP, ED, AV, OS, and OA (labeled "With Outpatient Visits"). The program was also run for both patients without a pre-existing condition of schizophrenia spectrum disorder or bipolar I disorder and those with a pre-existing condition of schizophrenia spectrum disorder or bipolar I disorder.

Please review the Notes below and refer to the Modular Program request for request specifications.

Request ID MPR21

Table 1 Table that includes (by drug product) the number of users, number of dispensings, and total days supplied overall, by age group, by sex, and by year along with the number of adverse events among users.

Table 2 Two tables that include the number of users by drug product, age group, and pre-existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

Figure 1 Figure that depicts of the number of users by drug product and pre-existence of schizophrenia spectrum disorder or bipolar I disorder.

Table 3 Two tables that include the number of days supplied by drug product, age group, and pre-existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

Figure 2 Figure that depicts of the number of days supplied by drug product and pre-existence of schizophrenia spectrum disorder or bipolar I disorder.

Table 4 Two tables that include the days supplied per user by drug product, age group, and pre-existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

Figure 3 Figure that depicts of the days supplied per user by drug product and pre-existence of schizophrenia spectrum disorder or bipolar I disorder.

Table 5 Two tables that include dispensings per user by drug product, age group, and pre-existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

Figure 4 Figure that depicts of dispensings per user by drug product and pre-existence of schizophrenia spectrum disorder or bipolar I disorder.

Table 6 Two tables that include days supplied per dispensing by drug product, age group, and pre-existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

Figure 5 Figure that depicts of days supplied per dispensing by drug product and pre-existence of schizophrenia spectrum disorder or bipolar I disorder.

Notes:

The specifications used a 183-day washout period to define new users. FDA's original specification provides treatment episode definitions and incident definitions. Please refer to the original specifications for details. In addition, the program was run for the entire time period. When examining the yearly stratification, note once an incident user is first encountered, this user will not be counted for subsequent years.

Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Table 1. Number of Users, Number of Dispensings, and Total Days Supplied by Drug Product, Age Group, Sex, and Year along with the Number of Adverse Events

		NO PRE-EXISTING CONDITIONS						WITH PRE-EXISTING CONDITIONS					
					WITH OUTPATIENT VISITS	NO OUTPATIENT VISITS				WITH OUTPATIENT VISITS	NO OUTPATIENT VISITS		
		Unique Patients	Dispensings	TotalDaysSupp	Number of Events	Number of Events	Unique Patients	Dispensings	TotalDaysSupp	Number of Events	Number of Events		
ARIPIPIRAZOLE	TOTAL	TOTAL	52,122	167,425	5,479,706	9	9	8,146	26,701	863,279	2	2	
	AGE GROUP	0 to 4	42	154	4,828	0	0	0	0	0	0	0	0
		5 to 9	1,267	5,421	172,030	0	0	47	174	4,874	0	0	
		10 to 19	8,410	28,202	909,765	2	2	894	3,238	101,892	0	0	
		20 to 44	19,830	58,009	1,844,342	3	3	3,822	11,974	382,189	1	1	
		45 to 64	18,540	62,030	2,101,137	1	1	2,848	9,433	313,195	1	1	
		65+	4,033	13,609	447,604	3	3	535	1,882	61,129	0	0	
	SEX	A	1	1	30	0	0	1	1	30	0	0	
		F	32,905	104,680	3,427,299	4	4	5,189	17,051	548,783	0	0	
		M	19,095	62,377	2,040,125	5	5	2,944	9,609	313,007	2	2	
U		121	367	12,252	0	0	12	40	1,459	0	0		
INDEX YEAR	2009	18,396	67,668	2,203,594	5	5	3,184	11,593	369,753	1	1		
	2010	31,400	96,155	3,158,281	4	4	4,683	14,656	478,899	1	1		
	2011	2,326	3,602	117,831	0	0	279	452	14,627	0	0		
ASENAPINE	TOTAL	TOTAL	1,251	3,254	96,571	0	0	575	1,604	47,666	0	0	
	AGE GROUP	0 to 4	0	0	0	0	0	0	0	0	0	0	
		5 to 9	5	12	360	0	0	0	0	0	0	0	
		10 to 19	107	285	8,622	0	0	40	131	4,250	0	0	
		20 to 44	593	1,455	42,248	0	0	289	779	22,543	0	0	
		45 to 64	496	1,352	41,393	0	0	227	630	19,450	0	0	
		65+	50	150	3,948	0	0	19	64	1,423	0	0	
	SEX	F	785	2,025	60,992	0	0	362	985	29,676	0	0	
		M	462	1,222	35,309	0	0	210	615	17,810	0	0	
		U	4	7	270	0	0	3	4	180	0	0	
INDEX YEAR	2009	105	271	7,335	0	0	47	106	3,015	0	0		
	2010	1,051	2,863	85,421	0	0	493	1,452	43,206	0	0		
	2011	95	120	3,815	0	0	35	46	1,445	0	0		
CLOZAPINE	TOTAL	TOTAL	517	7,248	79,542	0	0	382	5,763	63,677	0	0	
	AGE GROUP	0 to 4	0	0	0	0	0	0	0	0	0	0	
		5 to 9	6	74	669	0	0	3	49	494	0	0	
		10 to 19	62	904	7,889	0	0	37	633	5,385	0	0	
		20 to 44	218	3,124	36,656	0	0	185	2,810	33,421	0	0	
		45 to 64	163	2,238	24,865	0	0	131	1,863	20,597	0	0	
		65+	68	908	9,463	0	0	26	408	3,780	0	0	
	SEX	F	243	3,543	38,000	0	0	186	2,839	30,798	0	0	
		M	274	3,705	41,542	0	0	196	2,924	32,879	0	0	
		U	0	0	0	0	0	0	0	0	0		
INDEX YEAR	2009	193	3,382	37,676	0	0	143	2,764	31,149	0	0		
	2010	300	3,769	40,966	0	0	224	2,942	31,993	0	0		
	2011	24	97	900	0	0	15	57	535	0	0		
ILOPERIDONE	TOTAL	TOTAL	299	782	22,445	0	0	166	474	14,392	0	0	
	AGE GROUP	0 to 4	0	0	0	0	0	0	0	0	0		
		5 to 9	1	1	90	0	0	0	0	0	0		
		10 to 19	26	60	1,681	0	0	9	24	726	0	0	
		20 to 44	152	384	11,396	0	0	99	268	8,266	0	0	
		45 to 64	107	299	8,303	0	0	53	158	4,736	0	0	
		65+	13	38	975	0	0	5	24	664	0	0	
	SEX	F	168	436	12,142	0	0	94	274	8,255	0	0	
		M	131	346	10,303	0	0	72	200	6,137	0	0	
		U	0	0	0	0	0	0	0	0	0		
INDEX YEAR	2009	0	0	0	0	0	0	0	0	0			
	2010	273	756	21,601	0	0	152	460	13,942	0	0		
	2011	26	26	844	0	0	14	14	450	0	0		

LURASIDONE	TOTAL	TOTAL	27	47	1,544	0	0	13	25	780	0	0
	AGE GROUP	0 to 4	0	0	0	.	.	0	0	0	.	.
		5 to 9	0	0	0	.	.	0	0	0	.	.
		10 to 19	2	2	74	0	0	1	1	60	0	0
		20 to 44	16	30	960	0	0	9	20	600	0	0
		45 to 64	9	15	510	0	0	3	4	120	0	0
		65+	0	0	0	.	.	0	0	0	.	.
	SEX	F	23	41	1,380	0	0	12	24	750	0	0
		M	4	6	164	0	0	1	1	30	0	0
		U	0	0	0	.	.	0	0	0	.	.
INDEX YEAR	2009	0	0	0	.	.	0	0	0	.	.	
	2010	0	0	0	.	.	0	0	0	.	.	
	2011	27	47	1,544	0	0	13	25	780	0	0	
OLANZAPINE	TOTAL	TOTAL	19,327	57,450	1,824,427	2	2	4,630	14,556	456,953	0	0
	AGE GROUP	0 to 4	6	8	189	0	0	1	1	30	0	0
		5 to 9	145	461	14,650	0	0	15	50	1,493	0	0
		10 to 19	1,486	4,403	133,684	0	0	390	1,212	36,590	0	0
		20 to 44	6,018	15,786	479,899	1	1	1,999	5,838	178,062	0	0
		45 to 64	6,192	18,122	592,491	0	0	1,615	5,105	165,751	0	0
		65+	5,480	18,670	603,514	1	1	610	2,350	75,027	0	0
	SEX	F	10,667	31,933	1,012,844	1	1	2,488	7,705	243,102	0	0
		M	8,642	25,434	808,918	1	1	2,138	6,842	213,589	0	0
		U	18	83	2,665	0	0	4	9	262	0	0
INDEX YEAR	2009	6,479	22,336	723,180	0	0	1,682	6,039	193,486	0	0	
	2010	11,843	33,465	1,052,138	2	2	2,735	8,171	252,937	0	0	
	2011	1,005	1,649	49,109	0	0	213	346	10,530	0	0	
PALIPERIDONE	TOTAL	TOTAL	1,812	6,274	186,254	0	0	774	2,686	79,297	0	0
	AGE GROUP	0 to 4	1	1	30	0	0	0	0	0	.	.
		5 to 9	46	178	5,397	0	0	8	18	513	0	0
		10 to 19	415	1,596	46,808	0	0	108	432	12,991	0	0
		20 to 44	765	2,510	73,931	0	0	364	1,203	34,931	0	0
		45 to 64	518	1,753	53,463	0	0	268	937	28,120	0	0
		65+	67	236	6,625	0	0	26	96	2,742	0	0
	SEX	F	926	2,952	88,371	0	0	407	1,348	39,769	0	0
		M	878	3,293	97,028	0	0	365	1,334	39,393	0	0
		U	8	29	855	0	0	2	4	135	0	0
INDEX YEAR	2009	781	2,824	80,976	0	0	330	1,144	33,253	0	0	
	2010	979	3,386	103,303	0	0	419	1,507	45,009	0	0	
	2011	52	64	1,975	0	0	25	35	1,035	0	0	
QUETIAPINE	TOTAL	TOTAL	71,415	228,931	7,454,219	8	8	9,375	32,338	1,009,582	1	1
	AGE GROUP	0 to 4	25	85	2,558	0	0	2	27	818	0	0
		5 to 9	532	2,099	66,694	0	0	32	171	4,940	0	0
		10 to 19	6,434	20,918	659,345	0	0	862	3,092	92,769	0	0
		20 to 44	23,705	68,039	2,079,451	3	3	4,019	12,981	390,069	0	0
		45 to 64	22,129	70,176	2,301,156	4	4	3,553	12,688	411,531	1	1
		65+	18,590	67,614	2,345,015	1	1	907	3,379	109,455	0	0
	SEX	A	1	1	50	0	0
		F	41,527	135,850	4,447,306	4	4	5,617	19,834	619,698	0	0
		M	29,807	92,780	2,998,185	4	4	3,748	12,448	388,329	1	1
U		80	300	8,678	0	0	10	56	1,555	0	0	
INDEX YEAR	2009	24,147	90,768	2,992,078	2	2	3,467	13,287	415,074	1	1	
	2010	43,667	132,469	4,287,110	6	6	5,522	18,400	574,264	0	0	
	2011	3,601	5,694	175,031	0	0	386	651	20,244	0	0	

RISPERIDONE	TOTAL	TOTAL	41,883	136,133	4,468,946	3	3	7,267	24,115	794,565	1	1
	AGE GROUP	0 to 4	208	742	23,213	0	0	2	9	270	0	0
		5 to 9	2,353	9,648	310,844	0	0	57	286	9,557	0	0
		10 to 19	6,723	22,015	712,210	0	0	676	2,213	67,073	0	0
		20 to 44	10,895	28,985	938,433	1	1	2,989	8,696	279,852	1	1
		45 to 64	9,616	30,012	1,029,041	0	0	2,626	9,179	311,744	0	0
		65+	12,088	44,731	1,455,205	2	2	917	3,732	126,069	0	0
	SEX	A	1	1	30	0	0	1	1	30	0	0
		F	22,231	72,301	2,378,342	2	2	4,099	13,359	441,510	0	0
		M	19,575	63,592	2,083,566	1	1	3,162	10,745	352,805	1	1
		U	76	239	7,008	0	0	5	10	220	0	0
	INDEX YEAR	2009	14,083	53,611	1,780,881	2	2	2,571	9,573	323,114	0	0
		2010	25,268	78,406	2,558,547	0	0	4,343	14,004	454,938	0	0
2011		2,532	4,116	129,518	1	1	353	538	16,513	1	1	
ZIPRASIDONE	TOTAL	TOTAL	10,274	33,490	1,047,345	3	3	3,605	12,266	381,078	1	1
	AGE GROUP	0 to 4	2	3	90	0	0	0	0	0	0	0
		5 to 9	133	521	16,716	0	0	11	47	1,308	0	0
		10 to 19	1,401	4,872	149,459	0	0	323	1,099	31,300	0	0
		20 to 44	4,409	13,671	420,267	1	1	1,787	5,863	180,121	0	0
		45 to 64	3,493	11,522	375,465	2	2	1,307	4,597	147,643	1	1
		65+	836	2,901	85,348	0	0	177	660	20,706	0	0
	SEX	A	1	1	30	0	0	1	1	30	0	0
		F	6,666	21,761	684,637	2	2	2,426	8,331	257,110	1	1
		M	3,586	11,641	359,846	1	1	1,167	3,868	122,126	0	0
		U	21	87	2,832	0	0	11	66	1,812	0	0
	INDEX YEAR	2009	3,814	14,071	441,669	2	2	1,330	5,123	163,432	0	0
		2010	5,963	18,587	580,109	1	1	2,121	6,901	210,301	1	1
2011		497	832	25,567	0	0	154	242	7,345	0	0	

Table 2a. Number of Users by Drug Product, Age Group, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	lloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	0 to 4 years	42	0	0	0	0	6	1	25	208	2
	5 to 9 years	1,267	5	6	1	0	145	46	532	2,353	133
	10 to 19 years	8,410	107	62	26	2	1,486	415	6,434	6,723	1,401
	20 to 44 years	19,830	593	218	152	16	6,018	765	23,705	10,895	4,409
	45 to 64 years	18,540	496	163	107	9	6,192	518	22,129	9,616	3,493
	65+ years	4,033	50	68	13	0	5,480	67	18,590	12,088	836
With Pre-Existing Conditions	0 to 4 years	0	0	0	0	0	1	0	2	2	0
	5 to 9 years	47	0	3	0	0	15	8	32	57	11
	10 to 19 years	894	40	37	9	1	390	108	862	676	323
	20 to 44 years	3,822	289	185	99	9	1,999	364	4,019	2,989	1,787
	45 to 64 years	2,848	227	131	53	3	1,615	268	3,553	2,626	1,307
	65+ years	535	19	26	5	0	610	26	907	917	177

Table 2b. Number of Users by Drug Product, Sex, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	lloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	Female	32,905	785	243	168	23	10,667	926	41,527	22,231	6,666
	Male	19,095	462	274	131	4	8,642	878	29,807	19,575	3,586
With Pre-Existing Conditions	Female	5,189	362	186	94	12	2,488	407	5,617	4,099	2,426
	Male	2,944	210	196	72	1	2,138	365	3,748	3,162	1,167

Figure 1. Number of Users by Drug Product and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder




Table 3a. Total Days Supplied by Drug Product, Age Group, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	lloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	0 to 4 years	4,828	0	0	0	0	189	30	2,558	23,213	90
	5 to 9 years	172,030	360	669	90	0	14,650	5,397	66,694	310,844	16,716
	10 to 19 years	909,765	8,622	7,889	1,681	74	133,684	46,808	659,345	712,210	149,459
	20 to 44 years	1,844,342	42,248	36,656	11,396	960	479,899	73,931	2,079,451	938,433	420,267
	45 to 64 years	2,101,137	41,393	24,865	8,303	510	592,491	53,463	2,301,156	1,029,041	375,465
	65+ years	447,604	3,948	9,463	975	0	603,514	6,625	2,345,015	1,455,205	85,348
With Pre-Existing Conditions	0 to 4 years	0	0	0	0	0	30	0	818	270	0
	5 to 9 years	4,874	0	494	0	0	1,493	513	4,940	9,557	1,308
	10 to 19 years	101,892	4,250	5,385	726	60	36,590	12,991	92,769	67,073	31,300
	20 to 44 years	382,189	22,543	33,421	8,266	600	178,062	34,931	390,069	279,852	180,121
	45 to 64 years	313,195	19,450	20,597	4,736	120	165,751	28,120	411,531	311,744	147,643
	65+ years	61,129	1,423	3,780	664	0	75,027	2,742	109,455	126,069	20,706

Table 3b. Total Days Supplied by Drug Product, Sex, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	lloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	Female	3,427,299	60,992	38,000	12,142	1,380	1,012,844	88,371	4,447,306	2,378,342	684,637
	Male	2,040,125	35,309	41,542	10,303	164	808,918	97,028	2,998,185	2,083,566	359,846
With Pre-Existing Conditions	Female	548,783	29,676	30,798	8,255	750	243,102	39,769	619,698	441,510	257,110
	Male	313,007	17,810	32,879	6,137	30	213,589	39,393	388,329	352,805	122,126

Figure 2. Total Days Supplied by Drug Product and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder




Table 4a. Days Supplied per User by Drug Product, Age Group, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	0 to 4 years	115.0	31.5	30.0	102.3	111.6	45.0
	5 to 9 years	135.8	72.0	111.5	90.0	.	101.0	117.3	125.4	132.1	125.7
	10 to 19 years	108.2	80.6	127.2	64.7	37.0	90.0	112.8	102.5	105.9	106.7
	20 to 44 years	93.0	71.2	168.1	75.0	60.0	79.7	96.6	87.7	86.1	95.3
	45 to 64 years	113.3	83.5	152.5	77.6	56.7	95.7	103.2	104.0	107.0	107.5
	65+ years	111.0	79.0	139.2	75.0	.	110.1	98.9	126.1	120.4	102.1
With Pre-Existing Conditions	0 to 4 years	30.0	.	409.0	135.0	.
	5 to 9 years	103.7	.	164.7	.	.	99.5	64.1	154.4	167.7	118.9
	10 to 19 years	114.0	106.3	145.5	80.7	60.0	93.8	120.3	107.6	99.2	96.9
	20 to 44 years	100.0	78.0	180.7	83.5	66.7	89.1	96.0	97.1	93.6	100.8
	45 to 64 years	110.0	85.7	157.2	89.4	40.0	102.6	104.9	115.8	118.7	113.0
	65+ years	114.3	74.9	145.4	132.8	.	123.0	105.5	120.7	137.5	117.0

Table 4b. Days Supplied per User by Drug Product, Sex, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	Female	104.2	77.7	156.4	72.3	60.0	95.0	95.4	107.1	107.0	102.7
	Male	106.8	76.4	151.6	78.6	41.0	93.6	110.5	100.6	106.4	100.3
With Pre-Existing Conditions	Female	105.8	82.0	165.6	87.8	62.5	97.7	97.7	110.3	107.7	106.0
	Male	106.3	84.8	167.8	85.2	30.0	99.9	107.9	103.6	111.6	104.6

Figure 3. Days Supplied per User by Drug Product and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder




Table 5a. Dispensings per User by Drug Product, Age Group, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	0 to 4 years	3.7	1.3	1.0	3.4	3.6	1.5
	5 to 9 years	4.3	2.4	12.3	1.0	.	3.2	3.9	3.9	4.1	3.9
	10 to 19 years	3.4	2.7	14.6	2.3	1.0	3.0	3.8	3.3	3.3	3.5
	20 to 44 years	2.9	2.5	14.3	2.5	1.9	2.6	3.3	2.9	2.7	3.1
	45 to 64 years	3.3	2.7	13.7	2.8	1.7	2.9	3.4	3.2	3.1	3.3
	65+ years	3.4	3.0	13.4	2.9	.	3.4	3.5	3.6	3.7	3.5
With Pre-Existing Conditions	0 to 4 years	1.0	.	13.5	4.5	.
	5 to 9 years	3.7	.	16.3	.	.	3.3	2.3	5.3	5.0	4.3
	10 to 19 years	3.6	3.3	17.1	2.7	1.0	3.1	4.0	3.6	3.3	3.4
	20 to 44 years	3.1	2.7	15.2	2.7	2.2	2.9	3.3	3.2	2.9	3.3
	45 to 64 years	3.3	2.8	14.2	3.0	1.3	3.2	3.5	3.6	3.5	3.5
	65+ years	3.5	3.4	15.7	4.8	.	3.9	3.7	3.7	4.1	3.7

Table 5b. Dispensings per User by Drug Product, Sex, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	Female	3.2	2.6	14.6	2.6	1.8	3.0	3.2	3.3	3.3	3.3
	Male	3.3	2.6	13.5	2.6	1.5	2.9	3.8	3.1	3.2	3.2
With Pre-Existing Conditions	Female	3.3	2.7	15.3	2.9	2.0	3.1	3.3	3.5	3.3	3.4
	Male	3.3	2.9	14.9	2.8	1.0	3.2	3.7	3.3	3.4	3.3

Figure 4. Dispensings per User by Drug Product and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder




Table 6a. Days Supplied per Dispensing by Drug Product, Age Group, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	0 to 4 years	31.4	23.6	30.0	30.1	31.3	30.0
	5 to 9 years	31.7	30.0	9.0	90.0	.	31.8	30.3	31.8	32.2	32.1
	10 to 19 years	32.3	30.3	8.7	28.0	37.0	30.4	29.3	31.5	32.4	30.7
	20 to 44 years	31.8	29.0	11.7	29.7	32.0	30.4	29.5	30.6	32.4	30.7
	45 to 64 years	33.9	30.6	11.1	27.8	34.0	32.7	30.5	32.8	34.3	32.6
65+ years	32.9	26.3	10.4	25.7	.	32.3	28.1	34.7	32.5	29.4	
With Pre-Existing Conditions	0 to 4 years	30.0	.	30.3	30.0	.
	5 to 9 years	28.0	.	10.1	.	.	29.9	28.5	28.9	33.4	27.8
	10 to 19 years	31.5	32.4	8.5	30.3	60.0	30.2	30.1	30.0	30.3	28.5
	20 to 44 years	31.9	28.9	11.9	30.8	30.0	30.5	29.0	30.0	32.2	30.7
	45 to 64 years	33.2	30.9	11.1	30.0	30.0	32.5	30.0	32.4	34.0	32.1
65+ years	32.5	22.2	9.3	27.7	.	31.9	28.6	32.4	33.8	31.4	

Table 6b. Days Supplied per Dispensing by Drug Product, Sex, and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

		Aripiprazole	Asenapine	Clozapine	Iloperidone	Lurasidone	Olanzapine	Paliperidone	Quetiapine	Risperidone	Ziprasidone
No Pre-Existing Conditions	Female	3.2	2.6	14.6	2.6	1.8	3.0	3.2	3.3	3.3	3.3
	Male	3.3	2.6	13.5	2.6	1.5	2.9	3.8	3.1	3.2	3.2
With Pre-Existing Conditions	Female	3.3	2.7	15.3	2.9	2.0	3.1	3.3	3.5	3.3	3.4
	Male	3.3	2.9	14.9	2.8	1.0	3.2	3.7	3.3	3.4	3.3

Figure 5. Days Supplied per Dispensing by Drug Product and Pre-Existence of Schizophrenia Spectrum Disorder or Bipolar I Disorder

